“…15 of these SNPs reached a genome wide significance level of <5 × 10 −8 in the original meta-analysis [24]. Based on the published literature and our results, 26 SNPs and corresponding genes are associated with T2D and have been previously reported, including those in PROX1 (rs340835) [37], IGF2BP2 (rs7651090) [38], WFS1 (rs734312) [39], CDKAL1 (rs10946403/rs7741604/rs10484634/rs1012635) [28,40–42], JAZF1 (rs849135) [43], KLF14 (rs4731702/rs13234407) [44,45], TP53INP1 (rs896854) [46], SLC30A8 (rs11558471) [47], HHEX (rs7911264) [48], ZMIZ1 (rs810517) [49], IDE/KIF11 (rs6583826) [50], TCF7L2 (rs4074720/rs7079711/rs290483/rs11196212) [51–54], HMGA2 (rs2261181) [55], CHR12 (rs7132840) [56], FTO (rs9940128/rs9930506/rs8057044) [51,57], HNF1B (rs4430796) [58], BCAR1 (rs9927309) [59]. Furthermore, 40 SNPs were identified as novel variants for T2D and annotated at 44 different genes, of which 23 genes have been reported to be significantly related with T2D in earlier researches [15,43,60–67], and remaining 21 genes were not previously detected in earlier T2D GWAS studies.…”